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Inflammation Underlying Chronic Respiratory Inflammatory Diseases” for your kind 
consideration for publication in the journal, Chemico Biological Interactions. The present review is 
original and has not been published elsewhere, nor is it currently under consideration for 
publication elsewhere.
Inflammatory response plays a remarkable role in the mechanisms of acute and chronic respiratory 
diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis and lung 
cancer. Herbal medicine has been widely used in therapeutics. Berberine, an alkaloid prominent in 
Chinese medicine, Rhizoma Coptis, has been shown to exert therapeutic properties in various diseases. 
Nevertheless, the number of researches focusing on the curative potential of Berberine in 
inflammatory diseases involving the respiratory system is limited. In this review, we focused on the 
anti-inflammatory properties of Berberine functioning through several pathways such as the NF-κB, 
ERK1/2 and p38 MAPK pathways, impacting several pro-inflammatory cytokines. We also discuss its 
role in the treatment of respiratory diseases, providing a new direction in the field of drug discovery 
with respect to respiratory diseases.
Our study, emphasizing the importance of berberine in combating respiratory inflammatory 
diseases, would be of great interest to pharmaceutical scientists, pharmacist and clinicians. Our 
study can form the basis for further detailed research in this field, which can help in targeting a 
better treatment option for respiratory inflammatory diseases. We hope that you find our review 
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Inflammatory responses play a remarkable role in the mechanisms of acute and chronic 
respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary 
fibrosis and lung cancer. Currently, there is a resurgence in the use of drugs from natural sources 
for various ailments as potent therapeutics. Berberine, an alkaloid prominent in the Chinese 
traditional system of medicine has been reported to exert therapeutic properties in various 
diseases. Nevertheless, the number of studies focusing on the curative potential of berberine in 
inflammatory diseases involving the respiratory system is limited. In this review, we have 
attempted to discuss the reported anti-inflammatory properties of berberine that function through 
several pathways such as, the NF-B, ERK1/2 and p38 MAPK pathways which affect several 
pro-inflammatory cytokines in the pathophysiological processes involved in chronic respiratory 
diseases. This review would serve to provide valuable information to researchers who work in 
this field and a new direction in the field of drug discovery with respect to respiratory diseases.
Keywords: Berberine; inflammatory diseases; respiratory diseases; COPD; asthma; pulmonary 
fibrosis; lung cancer.
1. Introduction
Inflammation is a defense response of the human body against injury or infectious agents 
with the primary intent to remove noxious stimuli and to promote healing.1,2 Signs and 
symptoms such as rubor, calor, tumor, dolor, and functio laesa, which are also known as redness, 
heat, swelling, pain and loss of function respectively are associated with the cellular and 
molecular events that occur during an inflammatory response.2 Ideally, acute inflammation 
resolves when the body homeostasis has been restored, after the injury or the invaded stimuli.1,3 
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However, uncontrolled and untreated inflammation can progress into various inflammatory 
diseases.
Inflammatory diseases that involve the respiratory system may impair gas exchange, 
resulting in hypoxia and eventually leading to death. The lungs are being constantly exposed to 
pathogens, allergens, irritants or toxic molecules in the atmosphere and thus, the pulmonary 
defense system is vital in protecting the integrity and function of the respiratory system. The 
balance between the inflammatory responses and the anti-inflammatory mechanism, therefore, 
are important in regulating lung homeostasis.4 Acute respiratory inflammation involves 
neutrophils while, chronic lung inflammation involves lymphocytes and macrophages. In acute 
pulmonary inflammation, chemotactic factors are expressed by activated endothelial cells, 
resulting in a chemotactic gradient that first causes the migration of neutrophils and then the 
production of chemokines.4 Acute respiratory distress syndrome (ARDS) and pneumonia are 
notable examples that results from acute pulmonary inflammation.5–7 Chronic respiratory 
inflammation, on the other hand, involves lymphocytes and macrophages and is the direct result 
of incomplete recovery from acute lung inflammation and its responses. In addition, chronic 
inflammation also includes the presence of necrotic debris and apoptotic cells which are the 
resultant products of the acute injury. 4 Chronic lung inflammation is often associated with 
chronic obstructive pulmonary disease (COPD), asthma, lung cancer and pulmonary fibrosis.5–7 
Plants have been widely used for medical purposes for thousands of years. Plants are 
known to relieve symptoms of various ailments.74 In several traditional systems of medicine 
namely, Ayurveda, Traditional Chinese Medicine (TCM) and Egyptian medicine, plants 
including herbs, are utilised for their medicinal properties for treating illnesses, improving health 
and disease prevention. 74 Herbal medicines in different forms target specific parts of the human 
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body.75 For instance, raw garlic aids in the respiratory system, treating asthma, whereas, mashed 
vinegar-macerated garlic relieves toothaches and sore throats.75 In the current era, herbal 
medicines have been massively replaced by modern drugs. Nonetheless, the use of herbal 
medicines is highly exercised throughout the world. 
Berberine is a benzylisoquinoline alkaloid (Figure 1) that can be normally found in the 
barks, stems, rhizomes or roots of various plant sources, including Arcangelisia flava (Yellow 
Fruit Moonseed), Berberis aquifolium (Oregon grape), Rhizoma coptidis (‘Huang Lian’), 
Berberis vulgaris (Barberry), Coptis chinensis (Coptis or Goldenthread), Berberis aristata (Tree 
Turmeric), Hydrastis Canadensis (Goldenseal), Phellodendron chinense (Chinese Cork Tree) 
and Phellodendron amurense (Amur cork tree).76–82 The first recorded use of berberine (Rhizoma 
coptidis) as folk medicine can be traced back to A.D. 200 in China, used by the father of Chinese 
medicine, Shennong.81–83 Rhizoma coptidis was traditionally used to treat the complications 
associated with diabetes for over 1500 years. Berberine containing plants were also widely used 
in ancient Ayurvedic medicine due to its anti-protozoal and anti-microbial activities.80 Among 
the various sources of berberine, Berberis aristata was widely mentioned in the scriptures of 
Ayurveda, Sushruta and Charaka.84 Berberis aristata was also used in homeopathy to treat 
diseases back in time. Some of the most common marketed formulations containing berberine 
that are sold in the US are listed in Table 2. Berberine, when subjected to pharmacokinetic 
studies, using rat plasma revealed the presence of four major metabolites, namely, berberrubine, 
thalifendine, demethyleneberberine, and jatrorrhizine, as free and glucuronide conjugates.
1.1.  Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) primarily corresponds to severe and 
prolonged inflammation of the airways. Tobacco smoke is recognised as one of the primary 
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causes of COPD, nevertheless,  air pollution, chemical fumes, poisonous gases, particlates and 
dust are also associated with disease onset. 8–10 Based on the Global Burden Disease Study 2017, 
COPD is one of the seven diseases that contributes to more than one million deaths each around 
the world. 11 People with COPD either experience chronic bronchiolitis, emphysema or a 
combination of both. Chronic bronchiolitis involves severe inflammation and swelling of the 
airways, eventually leading to a decreased size of the airways. Emphysema, on the other hand, is 
specifically characterized as the loss of elasticity of the alveoli wall which prevents the emptying 
of air and therefore, results in breathing difficulty. This condition, eventually over a period of 
time,  culminates in shortness of breath (dyspnea). 8–10,12 In COPD, there is an elevation in the 
levels of neutrophils and macrophages. Barnes et al., reported that activated macrophages release 
high levels of inflammatory mediators such as IL-6, IL-1β and TNF- Exposures to cigarette 
smoke (CS) and lipopolysaccharides (LPS) remarkably elevate inflammatory cell counts, 
specifically the neutrophil counts. Furthermore, CS and LPS exposures increase the levels of 
pro-inflammatory cytokines namely, TNF-, IL-1β and IL-6. Exposure to LPS along with 
elevated TNF- level increase phosphorylation of the transcription factor, nuclear factor-κB 
(NF-κB), causing the degradation of IB. This then causes production of induced nitric oxide 
synthase (iNOS) and matrix metalloproteinases (MMPs).13,14 Expression of iNOS induced by 
cytokines further causes the production of nitric oxide, promoting inflammatory response of 
pulmonary cells.15,16 Furthermore, MMPs are endopeptidases that destroy the matrix proteins, 
leading to the destruction of the normal structure of alveoli, exacerbating pulmonary 
inflammation and eventually inducing emphysema. All these factors contribute to a loss in the 
lung function.13,17 Based on the American College of Physicians Clinical Practice guidelines, the 
first-line management of COPD is monotherapy with either long-acting β-agonist (LABA) or 
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inhaled anticholinergic.18,19 However, treatment with LABA has been reported to induce several 
adverse effects including tremor, palpitation, arrythmias and cardiac ischaemia.20
1.2.  Asthma
Asthma is the result of reversible airway obstruction, resulting from airway inflammation 
and hyperresponsiveness.21 The clinical symptoms of asthma involve shortness of breath, 
wheezing, chest tightness and sometimes cough, where death can occur if the symptoms do not 
relieve on time.22 According to a systematic analysis by Abajobir et al., in 2015, asthma has the 
highest prevalence compared to other chronic respiratory diseases throughout the world.23 
However, the death rate of asthma had decreased 26.7% as compared from the year 1990, with 
1% of global disability-adjusted life years (DALYs) from the earlier 2.6% of global DALYs.23 
Asthma is a hyper-responsive allergic reaction in the airways that is normally acquired in all 
ages. Atopic asthma is commonly acquired in the childhood, where the airway inflammation 
involves over-reaction of specific immunoglobulin E (IgE) antibodies.24 
Although asthma is still incurable, inhaled corticosteroids (ICS) are the first line 
management for patient with persistent asthma.25 This is because ICS are effective in controlling 
asthma exacerbation even at a low dose.25 However, ICS work only by suppressing the 
inflammatory reactions in the airway, without providing a perfect solution for asthma cure. 25 
Other than that, high dose use of ICS in patients with severe asthma might be associated with 
local and systemic side effect such as oral candidiasis, bruising and cataracts.25 
In asthmatic patients, the defective airway epithelial barrier allows the stimulus to pass 
through the airway tissues 26 which triggers an immune response, leading to narrowing of the 
airway and hypersecretion of airway mucus.26 NF-κB and caspase-1 signalling pathways play an 
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essential role in the pathophysiology of asthma.27–31 Both pathways involve in thymic stromal 
lymphopoietin (TSLP) production, which is highly related to the pathogenesis of atopic asthma 
and other allergic diseases.27,28,32–37 TSLP is a pro-allergic cytokine that acts on a variety of cells 
during inflammatory events, including eosinophils, basophils, dendritic cells, mast cells, B cells, 
innate type II cells, CD4(+) T cells, CD8(+) T cells, natural killer T cells, as well as, epithelial 
cells.38–40 Other than regulating the production of TSLP, NF-κB signalling pathway also 
regulates the production of inflammatory cytokines and immunoglobulins in asthma.29–31 
Activation of NF-κB signaling pathways can increase the production of inflammatory cytokines 
such as IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, and IL-17.41 Increased production of IL-2, IL-5 and 
IL-13 from T-helper (Th)2 cells will subsequently increase the production of B-lymphocyte IgE, 
leading to asthmatic reactions.41,42 Moreover, prolonged eosinophil inflammation during asthma 
episodes is mainly caused by delayed eosinophil apoptosis, which is also regulated by NF-κB in 
the body.43–45 In other words, NF-κB pathway also plays a vital role in the infiltration and 
function of the inflammatory cells. To conclude with all the existing findings, the suppression of 
NF-κB and caspase-1 signalling pathways might be an alternative approach in the therapeutic 
intervention of asthma medication.
1.3.  Pulmonary fibrosis
Pulmonary fibrosis is a chronic pulmonary disease which is often caused by dysregulated 
healing of a lung injury.46,47 Pulmonary fibrosis is characterized by worsening lung functions 
along with respiratory failure. This condition is associated with high mortality and economic 
burden.46–48 Idiopathic pulmonary fibrosis (IPF), which is caused by unknown factors, is the 
most common type of pulmonary fibrosis diagnosed worldwide. 46–48 Although, there are no 
comprehensive systematic reviews on IPF to date, the incidences of IPF in North America and 
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Europe were in the range of 3-9 per 100,000 cases each year, according to the data compiled by 
Hutchinson et al. 49 Pulmonary fibrosis is considered as a rare disease, but the incidence rates 
and severity have increased over the years.50 In normal conditions, the lungs when injured by 
noxious agents will go through different phases of wound healing, namely, injury, inflammation, 
and repair. Following the wound-healing processes, the damage of the injured organ will be 
minimized, and the architecture of the lung tissue will be restored to reacquire normal 
function.46,47 However, repetitive stimulation and injury of the lung tissue with noxious agents 
such as toxic chemical, allergens, radiation or other unknown factors may result in the 
dysregulation of the tissue repair responses, triggering a persistent inflammatory response.46–48  
The extensive and recurring inflammation will then progressively evolve into pathogenic fibrotic 
response, causing fibrosis in the lungs and eventually impair the exchange of gases in the 
system.46–48
Pulmonary fibrosis is normally associated with significant histological changes in lung 
architecture, mostly caused by extensive mesenchymal cell proliferation, that eventually lead to 
excessive collagen deposition.51 High levels of hydroxyproline often reflects the accumulation of 
collagen in the lung tissues.52,53 In addition to that, mast cell proliferation also contributes a 
essential role in the pathogenesis of pulmonary fibrosis. During the inflammatory response, 
degranulated mast cells release histamine, which increases the secretion of fibrogenic cytokines 
via the upregulation of fibroblast activation.54,55  
Similar to other chronic respiratory diseases, NF-κB signalling pathway is also involved 
in the pathophysiology of pulmonary fibrosis. Activation of NF-κB pathway is associated with 
elevation in the levels of nitric oxide synthase (iNOS), TGF-β1, and TNF-α.54 Enhanced 
activation of iNOS increases the production of nitric oxide (NO) in the body, resulting in severe 
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oxidative stress. Free radical peroxidation products produced under increased oxidative stress, 
causes the destruction of cell membrane and eventually leads to pulmonary fibrosis.56,57 On the 
other hand, increased levels of multi-function cytokines, namely, TGF-β1 are highly associated 
to the pathogenesis of pulmonary fibrosis, as they stimulate the growth of myofibroblasts and 
fibroblasts, promoting the synthesis and deposition of extracellular matrix (ECM) and suppress 
the degradation of collagen while promoting its deposition and synthesis in the lung tissue.54,58,59 
Moreover, pulmonary fibrosis is also associated with oxidative tissue damage, which is 
often indicated by increased activity of malondialdehyde (MDA), hydroperoxides (OH) and 
nitrite (NO).54,60,61 The redox sensing transcription factor, nuclear factor E2-related factor 2 
(Nrf2) also plays a vital role in maintaining the balance between the activity of oxidants and 
antioxidants in the cells.54 Dysregulated Nrf2 is often one of the factors that is associated with 
aggravating pulmonary fibrosis. In addition, inflammatory cell infiltration often contributes an 
essential role in the pathophysiology of pulmonary fibrosis, and the level of myeloperoxidase 
(MPO) can be used to indicate the degree of neutrophilic accumulation in the body tissue.62
To date, the only cure available for IPF is lung transplantation and the most recent first 
line antifibrotic agents approved by the FDA (pirfenidone and nintedanib) can only stabilize and 
delay the disease progression in IPF, without providing absolute cure from the disease.48,63 
Therefore, further efforts are needed to discover advanced and potent pharmacotherapy for 
pulmonary fibrosis.
1.4.  Lung Cancer
Lung cancer is another respiratory disease that involves the inflammatory response and 
has the highest mortality rate worldwide. 64 Based on the Global Cancer Statistics 2018, lung 
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cancer has the highest incidence rate, contributing to 11.6% of all cancer diagnosis. Lung cancer, 
being the leading cause of cancer deaths, comprises of 18.4% of cancer deaths in total with an 
estimation of over 1.8 million deaths over a year. 64 Lung cancer can be categorised into two 
major types; non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The 
diagnosis rate of NSCLC (85%) is comparably higher than SCLC (15%), with a ratio of 
approximately 5:1. 65,66 SCLC first appears in the bronchi, which is located in the center of the 
chest. NSCLC on the other hand, can be further categorized into three sub-classifications, 
namely adenocarcinoma (40%), squamous-cell carcinoma (30%) and large-cell lung cancer 
(10%). In particular, squamous-cell carcinoma is most closely linked with cigarette smoking. 65 
According to Hanahan et al., the main indications of cancer, in general, include uncontrollable 
cell proliferation, eluding of growth factors, angiogenesis, invasions of hyper-proliferating cells 
and metastasis. 67 Inflammatory molecules play a crucial role in the development of lung cancer 
involving several events that may affect the malignancy of tumours. Gomes et al., reported that 
inflammatory cells function as tumour promoters that are responsible in the formation of 
malignant tumours from initiated cells. The dysregulation of cell growth results in the production 
of inflammatory molecules, including chemokines and cytokines that facilitate the development 
of cancer. TNF-, NF-B and TGF- are a few of the cytokines that contribute towards the 
development of cancer. 66 P38 mitogen activated protein kinase (p38/MAPK), particularly p38δ, 
has been reported to suppress cell proliferation. Nonetheless, in lung cancer, the activated p38 is 
downregulated, and hence, initiates cell growth. 68 Moreover, signal transducer and activator of 
transcription 3 (STAT3) is a transcription factor that plays a significant role in the pathogenesis 
of lung cancer. The activation of STAT3 not only promotes cell proliferation, but also initiates 
survival of tumour cells. 69 The treatment of SCLC is divided in to two stages, namely limited 
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stage (LS) and extensive stage (ES). In the study conducted by Kalemkerian et al., the standard 
treatment of LS-SCLC is chemotherapy with carboplatin or cisplatin, with the addition of 
etoposide for approximately 4 to 6 cycles, together with early, concurrent thoracic radiotherapy 
(RT). As for patients with stage 1 LS-SCLC, the treatment option is surgical excision followed 
by adjuvant chemotherapy. Patients with ES-SCLC on the other hand, can be treated with 
platinum-based chemotherapy of two drugs such as cisplatin and etoposide for 4 to 6 cycles, 
followed by prophylactic cranial irradiation (PCI) if patients respond well to initial 
chemotherapy. 70–72 Furthermore, stage I, II and IIIA NSCLC patients can be treated with 
surgical resection, whereas, patients with stage IIA, IIB and IIIA NSCLC normally receive 
chemotherapy following surgery to ensure all remaining cancer cells are killed.  Nonetheless, 
radiotherapy is the alternative treatment for patients who are not suitable for surgery and do not 
respond to chemotherapy. 73
2. The role of berberine in respiratory inflammatory diseases
2.1. Berberine and COPD
HwangRyunHaeDok-Tang (HRHD), an Eastern herbal formula, used not only in China, 
but also in Korea and Japan to treat inflammatory diseases, contains 4 major constituents. 85 One 
of the main components of HRHD is Coptidis rhizoma, which contains the anti-inflammatory 
substance, berberine. 13,85 A study conducted by Shin et al., reported a decrease in neutrophil 
counts in the broncho-alveolar lavage fluid (BALF) in HRHD treated animals. The rats were 
administered with either 100mg/kg or 200mg/kg of the formulation. Moreover, HRHD-treated 
organisms are found to have reduced levels of TNF-  IL-1B and IL-6.  HRHD is also found to 
inhibit NF-κB activation, eventually decreasing its activity, which then results in the suppression 
of inflammatory responses caused by both CS and LPS exposures. The increased expression and 
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activity of MMPs are also suppressed in HRHD-administered animals. 13 Another study 
conducted by Lin et al., reported that berberine, at a dose of 50mg/kg, when administered 
intragastrically, significantly caused a decline in the number of neutrophils and total cells in 
BALF. Myeloperoxidase (MPO) activity that indicates the neutrophil accumulation in the lungs, 
caused by CS exposure, is also reduced in berberine-administered mice. Decrease in pro-
inflammatory cytokine (TNF- and IL-6) levels is also noticed in berberine-treated mice. 
Besides, berberine also causes a crucial decrease in NF-B nuclear translocation and its DNA 
activity.  86 Li et al., reported that berberine pre-treatment at 1.25 μM concentration decreases the 
mRNA expression of iNOS. Cell lines treated with berberine demonstrated a suppressive effect 
on the levels of pro-inflammatory cytokines (TNF-, IL-1β and IL-6). In in vivo studies, 
berberine at a dose of 20 mg/kg demonstrated a significant reduction in inflammation in mice. 
Berberine has also shown inhibitory effect on the phosphorylation of NF-B and IB. 87  Xu et 
al., also reported in their study that berberine reduces the accumulation of total cells in BALF, at 
the same time, suppresses the entry of neutrophils into BALF. Levels of inflammatory mediators 
(TNF-, IL-1 and MCP-1) were found to be remarkably reduced in berberine-treated mice at 
doses of either 5 mg/kg or 10 mg/kg. In addition, p38MAPK activity that portrays an important 
role in COPD is found to be attenuated in mice administered with berberine.88 Hence, the anti-
inflammatory properties of berberine presents a potential case in the treatment of COPD. 
2.2. Berberine and asthma
High levels of TSLP expressions have been detected in asthmatic airways in human and 
animal models, and researchers suggest that suppression of TSLP will be a positive approach to 
modulate allergic inflammatory diseases including asthma.32–37 Berberine has shown to suppress 
TSLP expression effectively. Based on the studies carried out by Moon et al., (2011), decreased 
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TSLP production and mRNA expression were observed in HMC-1 cells in berberine treatment 
group of different concentrations without showing cytotoxicity.36 The TSLP production was also 
reduced in primary mast cells under the treatment of berberine. The researchers concluded that 
the low TSLP production is highly associated to the downregulation of NF-κB and caspase-1 
pathway in HMC-1 cells by berberine.27,28 These results proved that TSLP production is 
governed by NF-κB and caspase-1 pathways, and inhibition of both these pathways can result in 
low TSLP production.27,28 The study also suggested that berberine can modulate the 
inflammatory response associated with PMA plus A23187 via inhibiting the production of TSLP, 
and berberine can be one of the potential therapeutic interventions in treating asthma.
In addition to regulating the production of TSLP, berberine also has been shown to 
inhibit NF-κB signalling pathway and its subsequent inflammatory response effectively. Li et al., 
studied the anti-inflammatory effects of berberine on ovalbumin-induced asthma in experimental 
rats.41 The rats were administered either 100 mg/kg or 200 mg/kg of berberine. Based on the 
results, the signalling of NF-κB pathway was inhibited by berberine treatment. When compared 
to berberine treatment group, vehicle group and control group, similar expression of IκBα 
(mRNA and protein) was observed. However, the NF-κB p65 (mRNA and protein), p-IκBα, and 
p-NF-κB p65 expression were found to be markedly lower in berberine treated group. The 
groups treated with berberine also showed lower NF-κB p65 DNA binding activity compared to 
the vehicle group. It also significantly reduced the levels of inflammatory cytokines (IL-1β, IL-4, 
IL-5, IL-6, IL-13, and IL-17) and OVA-specific IgE in BALF in contrast with the vehicle group 
in a dose-dependent pattern. It is hypothesized that NF-κB pathway regulates the production of 
inflammatory cytokines, and suppression of this pathway by berberine decreases the level of 
inflammatory cytokines. 41 Suppression of NF-κB pathway also indirectly decreases the 
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production of B-lymphocyte IgE due to low production of cytokines such as IL-2, IL-5 and IL-13 
by Th2 cells.41,42 Besides, the inflammatory scores of the treatment groups (both low-dose and 
high-dose group) were markedly decreased compared to vehicle group, suggesting that berberine 
was able to decrease the infiltration of the inflammatory cells in asthmatic lung tissue.  These 
results suggested that the NF-κB pathway inhibition by berberine can induce eosinophil 
apoptosis, thus reducing the inflammatory response.44,45 In addition, the amount of the 
inflammatory cells (neutrophil, eosinophils, lymphocytes, and macrophages) present in BALF of 
the group treated with berberine were markedly reduced compared to the vehicle group treated 
only with PBS (P< 0.05). Overall, berberine was effective in suppressing the inflammatory 
response of ovalbumin-induced asthma in rat model with a dose-dependent manner via inhibition 
of the over-reactive NF-κB signalling pathway. 
2.3. Effect of berberine on pulmonary fibrosis
Pulmonary fibrosis is normally associated with significant histological changes in the 
lung architecture following pathogenic fibrotic response.51  Based on the study carried out by 
Chitra et al., berberine reduces the histological changes mediated by bleomycin in the lung tissue 
of rat models.54 The Ashcroft quantitative pathological scoring of berberine treatment group was 
significantly lower than the bleomycin-induced rat model.54 Berberine also reduced the level of 
hydroxyproline, the recruitment of mast cell and histamine release in bleomycin-induced rat 
model. 54 These results suggest that berberine significantly reduces the accumulation and 
deposition of collagen, thus slowing the histological alterations in pulmonary fibrosis.
In addition to that, studies have also reported that suppression of NF-κB signalling 
pathway may alleviate the progress of pulmonary fibrosis.54,58,59 According to the study carried 
out by Chitra et al., the activation of NF-κB signalling pathway was significantly downregulated 
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in the berberine treatment group compared to the bleomycin induced animal groups, suggesting 
that berberine is effective in suppressing NF-κB signalling pathway.54 The treatment group also 
showed significantly lower expression of iNOS, TGF-β1 and TNF-α, which most likely resulted 
from the downregulating NF-κB activation. The studies revealed that berberine inhibits TGF-β1 
via the activation of Smad 7 and inhibition of Smad 2/3 activation.89 In addition, the study by 
Javad-Mousavi et al., also revealed that the treatment groups that received an oral dose of either 
100 mg/kg, 200 mg/kg or 400 mg/kg of the Berberis vulgaris fruit extract have significantly 
lower TGF-β1 and TNF-α compared to the group which was exposed only to paraquat.90
Studies also showed that berberine can increase the levels of antioxidants in the body, 
consequently decreasing the oxidative stress. Based on previous studies, the induction of Nrf2 
expression with antioxidants may be a therapeutic intervention to suppress the progression of 
pulmonary fibrosis.54,91 The study carried out by Chitra et al., prove that berberine treatment can 
reduce the levels of MDA, OH and NO in both BALF and lung tissue compared to bleomycin-
induced rat model.54 Besides that, the Nrf2 expression was also significantly higher in the 
berberine treated group, suggesting that the upregulation of the antioxidant levels was through 
the activation of Nrf2 expression.54  Comparatively, berberine treatment group showed more 
efficacy in reducing oxidative stress at the preventive phase (0-14 days) compared to therapeutic 
phase (14-28 days), and this may be due to the nature of berberine that scavenge free radical 
produced, which inhibits the free radical chain reaction in the initial phase.54
Other than that, several studies have also suggested that berberine has the ability to 
reduce the levels of other inflammatory mediators. Based on the study carried out by Chitra et 
al., the level of MPO was increased in the bleomycin-induced control group and berberine 
treatment significantly reduce the level of MPO in both therapeutic and preventive aspects.54 
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This suggested that berberine can reduce neutrophil accumulation in the bleomycin-induced lung 
tissue. Besides, based on the study carried out by Javad-Mousavi et al., berberine treatment 
group also showed reduced pleiotropic cytokine, interleukin (IL)-6, which is involved in 
inflammation, haematopoiesis, and immune responses.90,92 The study carried out by Guan et al., 
showed that berberine can increase the mRNA expression of human growth factor (HGF) and 
phosphatase and tensin homolog (PTEN) in the colon after oral administration.93 However, the 
study shows that upregulation of HGF secretion is the key mechanism for the anti-fibrotic effect 
of berberine, where the increased HGF secretion is highly associated with the PPAR-γ activation 
by berberine.93
2.4. Effect of berberine in lung cancer
A study conducted by Fang Zheng et al., reported that berberine reduces the cell viability 
of NSCLC cells (A549). Berberine disrupts the events in the G0/G1 phase of cell cycle in which 
the proportions of cells in the particular phase is found to be increased, indicating the initiation 
of cell cycle arrest in that phase. Furthermore, the presence of marked granular apoptotic bodies 
as well as increased rate of apoptosis are observed in berberine-treated cell lines. These 
conditions signify the ability of berberine to initiate apoptosis of NSCLC cells. 94 Extracellular 
single-regulated kinase1/2 (ERK1/2) and p38 mitogen activated protein kinase (p38/MAPK) are 
both involved in cell apoptosis. Berberine, as shown in the study, increases the activation of both 
ERK1/2 and p38/MAPK, eventually increasing cell apoptosis. 94,95 Forkhead homeobox type 
O3a (FOXO3a) is a tumour suppressor that is activated to upregulate the expression of proteins 
involved in cell cycle arrest and apoptosis. 94,96 Berberine plays its role in suppressing tumour by 
increasing the activity of FOXO3a. 94
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In a study investigated by Santosh et al., it is proved that berberine causes a decrease in 
cell viability of NSCLC cells, eventually resulting in the inhibition of proliferation of NSCLC 
cells. Bax and Bak are examples of pro-apoptotic proteins, whereas, BcI-2 and BcI-x1 are anti-
apoptotic proteins. Berberine causes overexpression of pro-apoptotic proteins and 
underexpression of anti-apoptotic proteins. The regulation mechanisms of these proteins by 
berberine contribute to the apoptosis of NSCLC cells. Additionally, the cancer cells become 
more susceptible to the berberine-induced apoptosis due to the increased ratio of Bax:BcI-2 by 
berberine. Moreover, berberine is shown to disrupt the mitochondrial membrane potential. The 
disruption of the membrane potential of mitochondria plays a crucial role in the initiation of cell 
apoptosis. This condition is indicated by the liberation of Cytochrome C and Smac/DIABLO into 
the cytosol, which activate caspase-3, initiating cell death. Berberine is also found to directly 
increase the levels of Cytochrome C and Smac/DIABLO in the cytosol. Other than that, the 
fluorescence emission of JC-1 dye turns from red to green, signifying that the mitochondrial 
membrane potential has been disrupted. In berberine treated cell lines, the number of cells that 
displays green fluorescence is elevated, indicating the increased disruption of membrane 
potential of mitochondria by berberine. 97 Hence, this shows the role of berberine in promoting 
cell apoptosis by interrupting the function of mitochondria of the cells. 
Another study carried out by Zhu et al., showed the anti-cancer effect of berberine. Cells 
in the S phase of the cell cycle are represented by EdU-positive cells. Berberine significantly 
decreased the number of EdU-positive cells. This again shows that berberine is able to inhibit 
cell proliferation in lung cancer. Besides, berberine is also found to induce early and late cell 
apoptosis. Tumour spheroids that consist of cancer stem-cells imitate in-vivo tumour. Berberine 
is observed to not only reduce the number and size of the tumour spheroids, but also to inhibit 
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the formation of these spheroids, indicating its ability to subside the formation of in-vivo tumours, 
such as NSCLC cells. 98 In lung cancer, STAT3 is activated. Berberine, nonetheless, suppresses 
the activated form of STAT3 which causes the inhibition of cell growth and initiation of 
apoptosis. 98,99
3. Future perspectives and conclusion
Preliminary studies have proven the anti-inflammatory effect of berberine in respiratory 
inflammatory diseases, that include COPD, asthma, pulmonary fibrosis and lung cancer. Based 
on the studies, berberine has been proven to activate the ERK1/2 & p38 MAPK, caspase-3 and 
FOXO3a pathways while inhibiting the activation of NF-κB and caspase-1 signalling pathways. 
Several studies have shown that berberine treatment group reduces the level of inflammatory 
cytokines (TNF-α , IL-6, IL-1B, MDA, OH and NO) as well as the inflammatory cell infiltration 
and collagen deposition. Berberine also decreased the activity of MPO and p38/MAPK, while 
reducing the mRNA expression of iNOS, TSLP and PTEN. The anti-apoptotic protein, BcI-2 & 
BcI-x1 are downregulated in berberine treatment group whereas the pro-apoptotic proteins (Bax 
& Bak) and Nrf2 expression were upregulated. These findings suggest the therapeutic potential 
of berberine in respiratory inflammatory diseases. However, there are several limitations with 
regard to the therapeutic applications of berberine. Firstly, there are not many clinical studies on 
berberine and secondly, the safety profile and toxicity of berberine are still not well-known due 
to limited number of studies, both preliminary and clinical.  Berberine exerts its cytotoxic effect 
only on lung cancer cells but not on non-neoplastic cells such as human bronchial epithelial cells, 
suggesting that berberine may cause limited side effects on non-neoplastic cells. 97 Thus, future 
studies are needed to further investigate the safety profile and toxicity of berberine, targeting 
inflammatory diseases in the respiratory system.
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HIGHLIGHTS
 Inflammatory responses play a crucial role in chronic respiratory diseases
 Berberine functions through the NF-kB, ERK1/2 and p38 MAPK pathways
 Berberine causes a decrease in pro-inflammatory cytokine levels
 Berberine improves the histological changes in the lung tissue of rat models
 Berberine suppresses tumours by increasing the activity of FOXO3a
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Inflammatory responses play a remarkable role in the mechanisms of acute and chronic 
respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary 
fibrosis and lung cancer. Currently, there is a resurgence in the use of drugs from natural sources 
for various ailments as potent therapeutics. Berberine, an alkaloid prominent in the Chinese 
traditional system of medicine has been reported to exert therapeutic properties in various 
diseases. Nevertheless, the number of studies focusing on the curative potential of berberine in 
inflammatory diseases involving the respiratory system is limited. In this review, we have 
attempted to discuss the reported anti-inflammatory properties of berberine that function through 
several pathways such as, the NF-B, ERK1/2 and p38 MAPK pathways which affect several 
pro-inflammatory cytokines in the pathophysiological processes involved in chronic respiratory 
diseases. This review would serve to provide valuable information to researchers who work in 
this field and a new direction in the field of drug discovery with respect to respiratory diseases.
Keywords: Berberine; inflammatory diseases; respiratory diseases; COPD; asthma; pulmonary 
fibrosis; lung cancer.
1. Introduction
Inflammation is a defense response of the human body against injury or infectious agents 
with the primary intent to remove noxious stimuli and to promote healing.1,2 Signs and 
symptoms such as rubor, calor, tumor, dolor, and functio laesa, which are also known as redness, 
heat, swelling, pain and loss of function respectively are associated with the cellular and 
molecular events that occur during an inflammatory response.2 Ideally, acute inflammation 
resolves when the body homeostasis has been restored, after the injury or the invaded stimuli.1,3 
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However, uncontrolled and untreated inflammation can progress into various inflammatory 
diseases.
Inflammatory diseases that involve the respiratory system may impair gas exchange, 
resulting in hypoxia and eventually leading to death. The lungs are being constantly exposed to 
pathogens, allergens, irritants or toxic molecules in the atmosphere and thus, the pulmonary 
defense system is vital in protecting the integrity and function of the respiratory system. The 
balance between the inflammatory responses and the anti-inflammatory mechanism, therefore, 
are important in regulating lung homeostasis.4 Acute respiratory inflammation involves 
neutrophils while, chronic lung inflammation involves lymphocytes and macrophages. In acute 
pulmonary inflammation, chemotactic factors are expressed by activated endothelial cells, 
resulting in a chemotactic gradient that first causes the migration of neutrophils and then the 
production of chemokines.4 Acute respiratory distress syndrome (ARDS) and pneumonia are 
notable examples that results from acute pulmonary inflammation.5–7 Chronic respiratory 
inflammation, on the other hand, involves lymphocytes and macrophages and is the direct result 
of incomplete recovery from acute lung inflammation and its responses. In addition, chronic 
inflammation also includes the presence of necrotic debris and apoptotic cells which are the 
resultant products of the acute injury. 4 Chronic lung inflammation is often associated with 
chronic obstructive pulmonary disease (COPD), asthma, lung cancer and pulmonary fibrosis.5–7 
Plants have been widely used for medical purposes for thousands of years. Plants are 
known to relieve symptoms of various ailments.74 In several traditional systems of medicine 
namely, Ayurveda, Traditional Chinese Medicine (TCM) and Egyptian medicine, plants 
including herbs, are utilised for their medicinal properties for treating illnesses, improving health 
and disease prevention. 74 Herbal medicines in different forms target specific parts of the human 
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body.75 For instance, raw garlic aids in the respiratory system, treating asthma, whereas, mashed 
vinegar-macerated garlic relieves toothaches and sore throats.75 In the current era, herbal 
medicines have been massively replaced by modern drugs. Nonetheless, the use of herbal 
medicines is highly exercised throughout the world. 
Berberine is a benzylisoquinoline alkaloid (Figure 1) that can be normally found in the 
barks, stems, rhizomes or roots of various plant sources, including Arcangelisia flava (Yellow 
Fruit Moonseed), Berberis aquifolium (Oregon grape), Rhizoma coptidis (‘Huang Lian’), 
Berberis vulgaris (Barberry), Coptis chinensis (Coptis or Goldenthread), Berberis aristata (Tree 
Turmeric), Hydrastis Canadensis (Goldenseal), Phellodendron chinense (Chinese Cork Tree) 
and Phellodendron amurense (Amur cork tree).76–82 The first recorded use of berberine (Rhizoma 
coptidis) as folk medicine can be traced back to A.D. 200 in China, used by the father of Chinese 
medicine, Shennong.81–83 Rhizoma coptidis was traditionally used to treat the complications 
associated with diabetes for over 1500 years. Berberine containing plants were also widely used 
in ancient Ayurvedic medicine due to its anti-protozoal and anti-microbial activities.80 Among 
the various sources of berberine, Berberis aristata was widely mentioned in the scriptures of 
Ayurveda, Sushruta and Charaka.84 Berberis aristata was also used in homeopathy to treat 
diseases back in time. Some of the most common marketed formulations containing berberine 
that are sold in the US are listed in Table 2. Berberine, when subjected to pharmacokinetic 
studies, using rat plasma revealed the presence of four major metabolites, namely, berberrubine, 
thalifendine, demethyleneberberine, and jatrorrhizine, as free and glucuronide conjugates.
1.1.  Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) primarily corresponds to severe and 
prolonged inflammation of the airways. Tobacco smoke is recognised as one of the primary 
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causes of COPD, nevertheless,  air pollution, chemical fumes, poisonous gases, particlates and 
dust are also associated with disease onset. 8–10 Based on the Global Burden Disease Study 2017, 
COPD is one of the seven diseases that contributes to more than one million deaths each around 
the world. 11 People with COPD either experience chronic bronchiolitis, emphysema or a 
combination of both. Chronic bronchiolitis involves severe inflammation and swelling of the 
airways, eventually leading to a decreased size of the airways. Emphysema, on the other hand, is 
specifically characterized as the loss of elasticity of the alveoli wall which prevents the emptying 
of air and therefore, results in breathing difficulty. This condition, eventually over a period of 
time,  culminates in shortness of breath (dyspnea). 8–10,12 In COPD, there is an elevation in the 
levels of neutrophils and macrophages. Barnes et al., reported that activated macrophages release 
high levels of inflammatory mediators such as IL-6, IL-1β and TNF- Exposures to cigarette 
smoke (CS) and lipopolysaccharides (LPS) remarkably elevate inflammatory cell counts, 
specifically the neutrophil counts. Furthermore, CS and LPS exposures increase the levels of 
pro-inflammatory cytokines namely, TNF-, IL-1β and IL-6. Exposure to LPS along with 
elevated TNF- level increase phosphorylation of the transcription factor, nuclear factor-κB 
(NF-κB), causing the degradation of IB. This then causes production of induced nitric oxide 
synthase (iNOS) and matrix metalloproteinases (MMPs).13,14 Expression of iNOS induced by 
cytokines further causes the production of nitric oxide, promoting inflammatory response of 
pulmonary cells.15,16 Furthermore, MMPs are endopeptidases that destroy the matrix proteins, 
leading to the destruction of the normal structure of alveoli, exacerbating pulmonary 
inflammation and eventually inducing emphysema. All these factors contribute to a loss in the 
lung function.13,17 Based on the American College of Physicians Clinical Practice guidelines, the 
first-line management of COPD is monotherapy with either long-acting β-agonist (LABA) or 
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inhaled anticholinergic.18,19 However, treatment with LABA has been reported to induce several 
adverse effects including tremor, palpitation, arrythmias and cardiac ischaemia.20
1.2.  Asthma
Asthma is the result of reversible airway obstruction, resulting from airway inflammation 
and hyperresponsiveness.21 The clinical symptoms of asthma involve shortness of breath, 
wheezing, chest tightness and sometimes cough, where death can occur if the symptoms do not 
relieve on time.22 According to a systematic analysis by Abajobir et al., in 2015, asthma has the 
highest prevalence compared to other chronic respiratory diseases throughout the world.23 
However, the death rate of asthma had decreased 26.7% as compared from the year 1990, with 
1% of global disability-adjusted life years (DALYs) from the earlier 2.6% of global DALYs.23 
Asthma is a hyper-responsive allergic reaction in the airways that is normally acquired in all 
ages. Atopic asthma is commonly acquired in the childhood, where the airway inflammation 
involves over-reaction of specific immunoglobulin E (IgE) antibodies.24 
Although asthma is still incurable, inhaled corticosteroids (ICS) are the first line 
management for patient with persistent asthma.25 This is because ICS are effective in controlling 
asthma exacerbation even at a low dose.25 However, ICS work only by suppressing the 
inflammatory reactions in the airway, without providing a perfect solution for asthma cure. 25 
Other than that, high dose use of ICS in patients with severe asthma might be associated with 
local and systemic side effect such as oral candidiasis, bruising and cataracts.25 
In asthmatic patients, the defective airway epithelial barrier allows the stimulus to pass 
through the airway tissues 26 which triggers an immune response, leading to narrowing of the 
airway and hypersecretion of airway mucus.26 NF-κB and caspase-1 signalling pathways play an 
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essential role in the pathophysiology of asthma.27–31 Both pathways involve in thymic stromal 
lymphopoietin (TSLP) production, which is highly related to the pathogenesis of atopic asthma 
and other allergic diseases.27,28,32–37 TSLP is a pro-allergic cytokine that acts on a variety of cells 
during inflammatory events, including eosinophils, basophils, dendritic cells, mast cells, B cells, 
innate type II cells, CD4(+) T cells, CD8(+) T cells, natural killer T cells, as well as, epithelial 
cells.38–40 Other than regulating the production of TSLP, NF-κB signalling pathway also 
regulates the production of inflammatory cytokines and immunoglobulins in asthma.29–31 
Activation of NF-κB signaling pathways can increase the production of inflammatory cytokines 
such as IL-1β, IL-2, IL-4, IL-5, IL-6, IL-13, and IL-17.41 Increased production of IL-2, IL-5 and 
IL-13 from T-helper (Th)2 cells will subsequently increase the production of B-lymphocyte IgE, 
leading to asthmatic reactions.41,42 Moreover, prolonged eosinophil inflammation during asthma 
episodes is mainly caused by delayed eosinophil apoptosis, which is also regulated by NF-κB in 
the body.43–45 In other words, NF-κB pathway also plays a vital role in the infiltration and 
function of the inflammatory cells. To conclude with all the existing findings, the suppression of 
NF-κB and caspase-1 signalling pathways might be an alternative approach in the therapeutic 
intervention of asthma medication.
1.3.  Pulmonary fibrosis
Pulmonary fibrosis is a chronic pulmonary disease which is often caused by dysregulated 
healing of a lung injury.46,47 Pulmonary fibrosis is characterized by worsening lung functions 
along with respiratory failure. This condition is associated with high mortality and economic 
burden.46–48 Idiopathic pulmonary fibrosis (IPF), which is caused by unknown factors, is the 
most common type of pulmonary fibrosis diagnosed worldwide. 46–48 Although, there are no 
comprehensive systematic reviews on IPF to date, the incidences of IPF in North America and 
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Europe were in the range of 3-9 per 100,000 cases each year, according to the data compiled by 
Hutchinson et al. 49 Pulmonary fibrosis is considered as a rare disease, but the incidence rates 
and severity have increased over the years.50 In normal conditions, the lungs when injured by 
noxious agents will go through different phases of wound healing, namely, injury, inflammation, 
and repair. Following the wound-healing processes, the damage of the injured organ will be 
minimized, and the architecture of the lung tissue will be restored to reacquire normal 
function.46,47 However, repetitive stimulation and injury of the lung tissue with noxious agents 
such as toxic chemical, allergens, radiation or other unknown factors may result in the 
dysregulation of the tissue repair responses, triggering a persistent inflammatory response.46–48  
The extensive and recurring inflammation will then progressively evolve into pathogenic fibrotic 
response, causing fibrosis in the lungs and eventually impair the exchange of gases in the 
system.46–48
Pulmonary fibrosis is normally associated with significant histological changes in lung 
architecture, mostly caused by extensive mesenchymal cell proliferation, that eventually lead to 
excessive collagen deposition.51 High levels of hydroxyproline often reflects the accumulation of 
collagen in the lung tissues.52,53 In addition to that, mast cell proliferation also contributes a 
essential role in the pathogenesis of pulmonary fibrosis. During the inflammatory response, 
degranulated mast cells release histamine, which increases the secretion of fibrogenic cytokines 
via the upregulation of fibroblast activation.54,55  
Similar to other chronic respiratory diseases, NF-κB signalling pathway is also involved 
in the pathophysiology of pulmonary fibrosis. Activation of NF-κB pathway is associated with 
elevation in the levels of nitric oxide synthase (iNOS), TGF-β1, and TNF-α.54 Enhanced 
activation of iNOS increases the production of nitric oxide (NO) in the body, resulting in severe 
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oxidative stress. Free radical peroxidation products produced under increased oxidative stress, 
causes the destruction of cell membrane and eventually leads to pulmonary fibrosis.56,57 On the 
other hand, increased levels of multi-function cytokines, namely, TGF-β1 are highly associated 
to the pathogenesis of pulmonary fibrosis, as they stimulate the growth of myofibroblasts and 
fibroblasts, promoting the synthesis and deposition of extracellular matrix (ECM) and suppress 
the degradation of collagen while promoting its deposition and synthesis in the lung tissue.54,58,59 
Moreover, pulmonary fibrosis is also associated with oxidative tissue damage, which is 
often indicated by increased activity of malondialdehyde (MDA), hydroperoxides (OH) and 
nitrite (NO).54,60,61 The redox sensing transcription factor, nuclear factor E2-related factor 2 
(Nrf2) also plays a vital role in maintaining the balance between the activity of oxidants and 
antioxidants in the cells.54 Dysregulated Nrf2 is often one of the factors that is associated with 
aggravating pulmonary fibrosis. In addition, inflammatory cell infiltration often contributes an 
essential role in the pathophysiology of pulmonary fibrosis, and the level of myeloperoxidase 
(MPO) can be used to indicate the degree of neutrophilic accumulation in the body tissue.62
To date, the only cure available for IPF is lung transplantation and the most recent first 
line antifibrotic agents approved by the FDA (pirfenidone and nintedanib) can only stabilize and 
delay the disease progression in IPF, without providing absolute cure from the disease.48,63 
Therefore, further efforts are needed to discover advanced and potent pharmacotherapy for 
pulmonary fibrosis.
1.4.  Lung Cancer
Lung cancer is another respiratory disease that involves the inflammatory response and 
has the highest mortality rate worldwide. 64 Based on the Global Cancer Statistics 2018, lung 
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cancer has the highest incidence rate, contributing to 11.6% of all cancer diagnosis. Lung cancer, 
being the leading cause of cancer deaths, comprises of 18.4% of cancer deaths in total with an 
estimation of over 1.8 million deaths over a year. 64 Lung cancer can be categorised into two 
major types; non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The 
diagnosis rate of NSCLC (85%) is comparably higher than SCLC (15%), with a ratio of 
approximately 5:1. 65,66 SCLC first appears in the bronchi, which is located in the center of the 
chest. NSCLC on the other hand, can be further categorized into three sub-classifications, 
namely adenocarcinoma (40%), squamous-cell carcinoma (30%) and large-cell lung cancer 
(10%). In particular, squamous-cell carcinoma is most closely linked with cigarette smoking. 65 
According to Hanahan et al., the main indications of cancer, in general, include uncontrollable 
cell proliferation, eluding of growth factors, angiogenesis, invasions of hyper-proliferating cells 
and metastasis. 67 Inflammatory molecules play a crucial role in the development of lung cancer 
involving several events that may affect the malignancy of tumours. Gomes et al., reported that 
inflammatory cells function as tumour promoters that are responsible in the formation of 
malignant tumours from initiated cells. The dysregulation of cell growth results in the production 
of inflammatory molecules, including chemokines and cytokines that facilitate the development 
of cancer. TNF-, NF-B and TGF- are a few of the cytokines that contribute towards the 
development of cancer. 66 P38 mitogen activated protein kinase (p38/MAPK), particularly p38δ, 
has been reported to suppress cell proliferation. Nonetheless, in lung cancer, the activated p38 is 
downregulated, and hence, initiates cell growth. 68 Moreover, signal transducer and activator of 
transcription 3 (STAT3) is a transcription factor that plays a significant role in the pathogenesis 
of lung cancer. The activation of STAT3 not only promotes cell proliferation, but also initiates 
survival of tumour cells. 69 The treatment of SCLC is divided in to two stages, namely limited 
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stage (LS) and extensive stage (ES). In the study conducted by Kalemkerian et al., the standard 
treatment of LS-SCLC is chemotherapy with carboplatin or cisplatin, with the addition of 
etoposide for approximately 4 to 6 cycles, together with early, concurrent thoracic radiotherapy 
(RT). As for patients with stage 1 LS-SCLC, the treatment option is surgical excision followed 
by adjuvant chemotherapy. Patients with ES-SCLC on the other hand, can be treated with 
platinum-based chemotherapy of two drugs such as cisplatin and etoposide for 4 to 6 cycles, 
followed by prophylactic cranial irradiation (PCI) if patients respond well to initial 
chemotherapy. 70–72 Furthermore, stage I, II and IIIA NSCLC patients can be treated with 
surgical resection, whereas, patients with stage IIA, IIB and IIIA NSCLC normally receive 
chemotherapy following surgery to ensure all remaining cancer cells are killed.  Nonetheless, 
radiotherapy is the alternative treatment for patients who are not suitable for surgery and do not 
respond to chemotherapy. 73
2. The role of berberine in respiratory inflammatory diseases
2.1. Berberine and COPD
HwangRyunHaeDok-Tang (HRHD), an Eastern herbal formula, used not only in China, 
but also in Korea and Japan to treat inflammatory diseases, contains 4 major constituents. 85 One 
of the main components of HRHD is Coptidis rhizoma, which contains the anti-inflammatory 
substance, berberine. 13,85 A study conducted by Shin et al., reported a decrease in neutrophil 
counts in the broncho-alveolar lavage fluid (BALF) in HRHD treated animals. The rats were 
administered with either 100mg/kg or 200mg/kg of the formulation. Moreover, HRHD-treated 
organisms are found to have reduced levels of TNF-  IL-1B and IL-6.  HRHD is also found to 
inhibit NF-κB activation, eventually decreasing its activity, which then results in the suppression 
of inflammatory responses caused by both CS and LPS exposures. The increased expression and 
13
activity of MMPs are also suppressed in HRHD-administered animals. 13 Another study 
conducted by Lin et al., reported that berberine, at a dose of 50mg/kg, when administered 
intragastrically, significantly caused a decline in the number of neutrophils and total cells in 
BALF. Myeloperoxidase (MPO) activity that indicates the neutrophil accumulation in the lungs, 
caused by CS exposure, is also reduced in berberine-administered mice. Decrease in pro-
inflammatory cytokine (TNF- and IL-6) levels is also noticed in berberine-treated mice. 
Besides, berberine also causes a crucial decrease in NF-B nuclear translocation and its DNA 
activity.  86 Li et al., reported that berberine pre-treatment at 1.25 μM concentration decreases the 
mRNA expression of iNOS. Cell lines treated with berberine demonstrated a suppressive effect 
on the levels of pro-inflammatory cytokines (TNF-, IL-1β and IL-6). In in vivo studies, 
berberine at a dose of 20 mg/kg demonstrated a significant reduction in inflammation in mice. 
Berberine has also shown inhibitory effect on the phosphorylation of NF-B and IB. 87  Xu et 
al., also reported in their study that berberine reduces the accumulation of total cells in BALF, at 
the same time, suppresses the entry of neutrophils into BALF. Levels of inflammatory mediators 
(TNF-, IL-1 and MCP-1) were found to be remarkably reduced in berberine-treated mice at 
doses of either 5 mg/kg or 10 mg/kg. In addition, p38MAPK activity that portrays an important 
role in COPD is found to be attenuated in mice administered with berberine.88 Hence, the anti-
inflammatory properties of berberine presents a potential case in the treatment of COPD. 
2.2. Berberine and asthma
High levels of TSLP expressions have been detected in asthmatic airways in human and 
animal models, and researchers suggest that suppression of TSLP will be a positive approach to 
modulate allergic inflammatory diseases including asthma.32–37 Berberine has shown to suppress 
TSLP expression effectively. Based on the studies carried out by Moon et al., (2011), decreased 
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TSLP production and mRNA expression were observed in HMC-1 cells in berberine treatment 
group of different concentrations without showing cytotoxicity.36 The TSLP production was also 
reduced in primary mast cells under the treatment of berberine. The researchers concluded that 
the low TSLP production is highly associated to the downregulation of NF-κB and caspase-1 
pathway in HMC-1 cells by berberine.27,28 These results proved that TSLP production is 
governed by NF-κB and caspase-1 pathways, and inhibition of both these pathways can result in 
low TSLP production.27,28 The study also suggested that berberine can modulate the 
inflammatory response associated with PMA plus A23187 via inhibiting the production of TSLP, 
and berberine can be one of the potential therapeutic interventions in treating asthma.
In addition to regulating the production of TSLP, berberine also has been shown to 
inhibit NF-κB signalling pathway and its subsequent inflammatory response effectively. Li et al., 
studied the anti-inflammatory effects of berberine on ovalbumin-induced asthma in experimental 
rats.41 The rats were administered either 100 mg/kg or 200 mg/kg of berberine. Based on the 
results, the signalling of NF-κB pathway was inhibited by berberine treatment. When compared 
to berberine treatment group, vehicle group and control group, similar expression of IκBα 
(mRNA and protein) was observed. However, the NF-κB p65 (mRNA and protein), p-IκBα, and 
p-NF-κB p65 expression were found to be markedly lower in berberine treated group. The 
groups treated with berberine also showed lower NF-κB p65 DNA binding activity compared to 
the vehicle group. It also significantly reduced the levels of inflammatory cytokines (IL-1β, IL-4, 
IL-5, IL-6, IL-13, and IL-17) and OVA-specific IgE in BALF in contrast with the vehicle group 
in a dose-dependent pattern. It is hypothesized that NF-κB pathway regulates the production of 
inflammatory cytokines, and suppression of this pathway by berberine decreases the level of 
inflammatory cytokines. 41 Suppression of NF-κB pathway also indirectly decreases the 
15
production of B-lymphocyte IgE due to low production of cytokines such as IL-2, IL-5 and IL-13 
by Th2 cells.41,42 Besides, the inflammatory scores of the treatment groups (both low-dose and 
high-dose group) were markedly decreased compared to vehicle group, suggesting that berberine 
was able to decrease the infiltration of the inflammatory cells in asthmatic lung tissue.  These 
results suggested that the NF-κB pathway inhibition by berberine can induce eosinophil 
apoptosis, thus reducing the inflammatory response.44,45 In addition, the amount of the 
inflammatory cells (neutrophil, eosinophils, lymphocytes, and macrophages) present in BALF of 
the group treated with berberine were markedly reduced compared to the vehicle group treated 
only with PBS (P< 0.05). Overall, berberine was effective in suppressing the inflammatory 
response of ovalbumin-induced asthma in rat model with a dose-dependent manner via inhibition 
of the over-reactive NF-κB signalling pathway. 
2.3. Effect of berberine on pulmonary fibrosis
Pulmonary fibrosis is normally associated with significant histological changes in the 
lung architecture following pathogenic fibrotic response.51  Based on the study carried out by 
Chitra et al., berberine reduces the histological changes mediated by bleomycin in the lung tissue 
of rat models.54 The Ashcroft quantitative pathological scoring of berberine treatment group was 
significantly lower than the bleomycin-induced rat model.54 Berberine also reduced the level of 
hydroxyproline, the recruitment of mast cell and histamine release in bleomycin-induced rat 
model. 54 These results suggest that berberine significantly reduces the accumulation and 
deposition of collagen, thus slowing the histological alterations in pulmonary fibrosis.
In addition to that, studies have also reported that suppression of NF-κB signalling 
pathway may alleviate the progress of pulmonary fibrosis.54,58,59 According to the study carried 
out by Chitra et al., the activation of NF-κB signalling pathway was significantly downregulated 
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in the berberine treatment group compared to the bleomycin induced animal groups, suggesting 
that berberine is effective in suppressing NF-κB signalling pathway.54 The treatment group also 
showed significantly lower expression of iNOS, TGF-β1 and TNF-α, which most likely resulted 
from the downregulating NF-κB activation. The studies revealed that berberine inhibits TGF-β1 
via the activation of Smad 7 and inhibition of Smad 2/3 activation.89 In addition, the study by 
Javad-Mousavi et al., also revealed that the treatment groups that received an oral dose of either 
100 mg/kg, 200 mg/kg or 400 mg/kg of the Berberis vulgaris fruit extract have significantly 
lower TGF-β1 and TNF-α compared to the group which was exposed only to paraquat.90
Studies also showed that berberine can increase the levels of antioxidants in the body, 
consequently decreasing the oxidative stress. Based on previous studies, the induction of Nrf2 
expression with antioxidants may be a therapeutic intervention to suppress the progression of 
pulmonary fibrosis.54,91 The study carried out by Chitra et al., prove that berberine treatment can 
reduce the levels of MDA, OH and NO in both BALF and lung tissue compared to bleomycin-
induced rat model.54 Besides that, the Nrf2 expression was also significantly higher in the 
berberine treated group, suggesting that the upregulation of the antioxidant levels was through 
the activation of Nrf2 expression.54  Comparatively, berberine treatment group showed more 
efficacy in reducing oxidative stress at the preventive phase (0-14 days) compared to therapeutic 
phase (14-28 days), and this may be due to the nature of berberine that scavenge free radical 
produced, which inhibits the free radical chain reaction in the initial phase.54
Other than that, several studies have also suggested that berberine has the ability to 
reduce the levels of other inflammatory mediators. Based on the study carried out by Chitra et 
al., the level of MPO was increased in the bleomycin-induced control group and berberine 
treatment significantly reduce the level of MPO in both therapeutic and preventive aspects.54 
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This suggested that berberine can reduce neutrophil accumulation in the bleomycin-induced lung 
tissue. Besides, based on the study carried out by Javad-Mousavi et al., berberine treatment 
group also showed reduced pleiotropic cytokine, interleukin (IL)-6, which is involved in 
inflammation, haematopoiesis, and immune responses.90,92 The study carried out by Guan et al., 
showed that berberine can increase the mRNA expression of human growth factor (HGF) and 
phosphatase and tensin homolog (PTEN) in the colon after oral administration.93 However, the 
study shows that upregulation of HGF secretion is the key mechanism for the anti-fibrotic effect 
of berberine, where the increased HGF secretion is highly associated with the PPAR-γ activation 
by berberine.93
2.4. Effect of berberine in lung cancer
A study conducted by Fang Zheng et al., reported that berberine reduces the cell viability 
of NSCLC cells (A549). Berberine disrupts the events in the G0/G1 phase of cell cycle in which 
the proportions of cells in the particular phase is found to be increased, indicating the initiation 
of cell cycle arrest in that phase. Furthermore, the presence of marked granular apoptotic bodies 
as well as increased rate of apoptosis are observed in berberine-treated cell lines. These 
conditions signify the ability of berberine to initiate apoptosis of NSCLC cells. 94 Extracellular 
single-regulated kinase1/2 (ERK1/2) and p38 mitogen activated protein kinase (p38/MAPK) are 
both involved in cell apoptosis. Berberine, as shown in the study, increases the activation of both 
ERK1/2 and p38/MAPK, eventually increasing cell apoptosis. 94,95 Forkhead homeobox type 
O3a (FOXO3a) is a tumour suppressor that is activated to upregulate the expression of proteins 
involved in cell cycle arrest and apoptosis. 94,96 Berberine plays its role in suppressing tumour by 
increasing the activity of FOXO3a. 94
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In a study investigated by Santosh et al., it is proved that berberine causes a decrease in 
cell viability of NSCLC cells, eventually resulting in the inhibition of proliferation of NSCLC 
cells. Bax and Bak are examples of pro-apoptotic proteins, whereas, BcI-2 and BcI-x1 are anti-
apoptotic proteins. Berberine causes overexpression of pro-apoptotic proteins and 
underexpression of anti-apoptotic proteins. The regulation mechanisms of these proteins by 
berberine contribute to the apoptosis of NSCLC cells. Additionally, the cancer cells become 
more susceptible to the berberine-induced apoptosis due to the increased ratio of Bax:BcI-2 by 
berberine. Moreover, berberine is shown to disrupt the mitochondrial membrane potential. The 
disruption of the membrane potential of mitochondria plays a crucial role in the initiation of cell 
apoptosis. This condition is indicated by the liberation of Cytochrome C and Smac/DIABLO into 
the cytosol, which activate caspase-3, initiating cell death. Berberine is also found to directly 
increase the levels of Cytochrome C and Smac/DIABLO in the cytosol. Other than that, the 
fluorescence emission of JC-1 dye turns from red to green, signifying that the mitochondrial 
membrane potential has been disrupted. In berberine treated cell lines, the number of cells that 
displays green fluorescence is elevated, indicating the increased disruption of membrane 
potential of mitochondria by berberine. 97 Hence, this shows the role of berberine in promoting 
cell apoptosis by interrupting the function of mitochondria of the cells. 
Another study carried out by Zhu et al., showed the anti-cancer effect of berberine. Cells 
in the S phase of the cell cycle are represented by EdU-positive cells. Berberine significantly 
decreased the number of EdU-positive cells. This again shows that berberine is able to inhibit 
cell proliferation in lung cancer. Besides, berberine is also found to induce early and late cell 
apoptosis. Tumour spheroids that consist of cancer stem-cells imitate in-vivo tumour. Berberine 
is observed to not only reduce the number and size of the tumour spheroids, but also to inhibit 
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the formation of these spheroids, indicating its ability to subside the formation of in-vivo tumours, 
such as NSCLC cells. 98 In lung cancer, STAT3 is activated. Berberine, nonetheless, suppresses 
the activated form of STAT3 which causes the inhibition of cell growth and initiation of 
apoptosis. 98,99
3. Future perspectives and conclusion
Preliminary studies have proven the anti-inflammatory effect of berberine in respiratory 
inflammatory diseases, that include COPD, asthma, pulmonary fibrosis and lung cancer. Based 
on the studies, berberine has been proven to activate the ERK1/2 & p38 MAPK, caspase-3 and 
FOXO3a pathways while inhibiting the activation of NF-κB and caspase-1 signalling pathways. 
Several studies have shown that berberine treatment group reduces the level of inflammatory 
cytokines (TNF-α , IL-6, IL-1B, MDA, OH and NO) as well as the inflammatory cell infiltration 
and collagen deposition. Berberine also decreased the activity of MPO and p38/MAPK, while 
reducing the mRNA expression of iNOS, TSLP and PTEN. The anti-apoptotic protein, BcI-2 & 
BcI-x1 are downregulated in berberine treatment group whereas the pro-apoptotic proteins (Bax 
& Bak) and Nrf2 expression were upregulated. These findings suggest the therapeutic potential 
of berberine in respiratory inflammatory diseases. However, there are several limitations with 
regard to the therapeutic applications of berberine. Firstly, there are not many clinical studies on 
berberine and secondly, the safety profile and toxicity of berberine are still not well-known due 
to limited number of studies, both preliminary and clinical.  Berberine exerts its cytotoxic effect 
only on lung cancer cells but not on non-neoplastic cells such as human bronchial epithelial cells, 
suggesting that berberine may cause limited side effects on non-neoplastic cells. 97 Thus, future 
studies are needed to further investigate the safety profile and toxicity of berberine, targeting 
inflammatory diseases in the respiratory system.
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Figure 1: The chemical structure of berberine
Figure 2: The effect of Berberine in NF-B signaling pathway   











 Inhibited NF-B activation 
in berberine-treated animals
 Decreased activity of NF-
B
 Reduced pro-inflammatory 
cytokines (IL-1, IL-6 and 
TNF-) levels
 Suppressed inflammatory 
response
Shin et al. 
(2017) 13
 Decreased NF-B nuclear 
translocation in berberine-
administered mice
 Decreased DNA activity of 
NF-B
 Declined pro-inflammatory 
cytokines (TNF-, IL-6) 
levels
Lin et al. (2013) 
86
 Inhibited phosphorylation 
of NF-B in berberine-
treated cell lines
 Regression of pro-
inflammatory cytokines 
(TNF-, IL-1, IL-6)
Li.C-L et al. 
(2019) 87
MPO  Reduced MPO activity in 
berberine-treated mice
 Reduced number of 
neutrophils in BALF




 Decreased neutrophil counts 
in BALF in berberine-
treated animals
Shin et al. 




 Decreased activity of 
p38/MAPK 
 Lowered levels of pro-
inflammatory cytokines 
(TNF-, IL-1, MCP-1)
Xu et al. (2015) 
88
iNOS  Decreased mRNA 
expression of iNOS
 Decreased inflammatory 
response





 Decreased the production of 
TSLP in HMC-1 cells and 
primary mast cells in 
berberine treatment group
 Decreased TSLP mRNA 
expression in HMC-1 cells 
in berberine treatment group




 Inhibit caspase-1 pathway 
activation, leading to low 
TSLP production






 Inhibit NF-κB signalling 
pathway activation, leading 
to low TSLP production
Moon et al. 
(2011) 36 
 Inhibition of the activation 
of NF-κB signalling 
pathway in berberine 
treatment group
 Lower NF-κB p65 (mRNA 
and protein), p-IκBα, and p-
NF-κB p65 expression
 Lower NF-κB p65 DNA 
binding activity
 Lower levels of 
inflammatory cytokines (IL-
1β, IL-4, IL-5, IL-6, IL-13, 
and IL-17) in BALF 
 Lower levels of OVA-
specific IgE in BALF
 Lower inflammatory scores 
in treatment group (Induced 
eosinophil apoptosis and 
reduce the inflammatory 
cell infiltration)
 Lower number of 









 Lower Ashcroft quantitative 
pathological scoring in 
berberine treatment group
Chitra et al. 
(2013) 54
 Reduced hydroxyproline 
level
 Decrease the level of mast 
cell recruitment
 Lower level of histamine 
released
 Inhibit NF-κB signalling 
pathway activation in 
berberine treatment group
 Lower expression of iNOS, 
TGF-β1, and TNF-α due to 
downregulated NF-κB 
signalling pathway
Chitra et al. 
(2013) 54
 Inhibit NF-κB signalling 
pathway activation via the 
activation of Smad 7 and 
inhibition of Smad 2/3 
activation





 Lower level of TNF-α and 
TGF-β1 in berberine 
treatment group
Javad-Mousavi 
et al. (2016) 90
Nrf2  Significant higher Nrf2 
expression in berberine 
treatment group
 Reduced level of MDA, OH 
and NO in both BALF and 
lung tissue treated with 
berberine
Chitra et al. 
(2013) 54
MPO  Significant reduction of 
MPO in berberine treatment 
group
 Reduced neutrophil 
accumulations
Chitra et al. 
(2013) 54
IL-6  Reduced level of IL-6 in 
berberine treatment group
Javad-Mousavi 
et al.  (2016) 90
HGF  Increased mRNA 
expression of HGF in the 
colon in berberine treatment 
group via oral 
administration
 increased HGF secretion is 
highly associated with the 
PPAR-γ activation by 
berberine
 Key mechanism for the 
Guan et al. 
(2017) 93
anti-fibrotic effect of 
berberine
PTEN  Increased mRNA 
expression of PTEN in the 
colon after oral 
administration of berberine
Guan et al. 
(2017) 93
Lung cancer ERK1/2 & p38 
MAPK pathway
 Increased ERK1/2 & p38 
MAPK activation in 
berberine-treated NSCLC 
cell lines (A549)
 Initiation of cell apoptosis
Zheng et al. 
(2014) 94
FOXO3a  Activation of FOXO3a in 
berberine-treated NSCLC 
cell lines (A549)
 Increased activity of 
FOXO3a
 Upregulation of expression 
of proteins involved in cell 
cycle and apoptosis
Zheng et al. 
(2014) 94
Pro-apoptotic 





 Upregulation of pro-
apoptotic protein (Bax & 
Bak) and downregulation of 
anti-apoptotic (BcI-2 & 
BcI-x1) in berberine-treated 
NSCLC cells (A549 & 
H1299)
 Initiation cell apoptosis
Santosh et al. 
(2009) 97
Caspase-3  Disruption of membrane 
potential of mitochondria in 
berberine-treated NSCLC 
cells (A549 & H1299)
 Liberation of cytochrome C 
and Smac/DIABLO into 
cytosol
 Caspase 3 activation
 Initiation of cell death
Santosh et al. 
(2009) 97
STAT 3  Suppressed activated form 
of STAT 3 in NSCLC cell 
lines (NCI-H460 & NCI-
H1975)
 Inhibition of cell 
proliferation
 Initiation of cell apoptosis
Zhu et al. (2015) 
98
Table 2: Most common supplements containing berberine that are manufactured in the US
No. Name of the marketed formulation Manufactured and 
marketed by
Active constituent
1. Sunergetic Premium Berberine 
Supplement
Sunergetic, USA Each pill contains 
berberine 
hydrochloride 
extract equivalent to 
1200mg of berberine
2. Thorne Research Berberine Thorne Research, 
USA
Each pill contains an 
equivalent amount 
of 1000mg of 
Berberine 
hydrochloride





of 500mg of Pure 
Berberine HCL
4. We Like Vitamins Berberine We Like Vitamins, 
USA
Each pill contains an 
equivalent amount 
of  900mg of 
Berberine HCL
5. Swanson Berberine Swanson Vitamins, 
USA
Each pill contains an 
equivalent amount 
of  400mg of 
Berberine HCL
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